Centiva Capital’s Tourmaline Bio TRML Stock Holding History
Bought
Maintained
Sold
Centiva Capital's TRML Position: Q4 2025 in Review
Centiva Capital sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 50,000 shares — an estimated $2.39M sold.
Centiva Capital first reported a position in TRML in Q3 2025 and held it in 1 quarter. The position peaked at $2.39M in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.
- Centiva Capital reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
- Centiva Capital sold 50,000 Tourmaline Bio shares in Q4 2025, an estimated $2.39M.
- Centiva Capital first reported a position in Tourmaline Bio in Q3 2025 and held it in 1 quarter.
- Centiva Capital's Tourmaline Bio position peaked at $2.39M in Q3 2025.
- 0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.
Based on Centiva Capital's 13F filing for Q4 2025, filed 13 Feb 2026.